RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Magenta Therapeutics Stock

Magenta Therapeutics ROCE 2024

Magenta Therapeutics ROCE

-0.76

Ticker

MGTA

ISIN

US55910K1088

WKN

A2JPD6

In 2024, Magenta Therapeutics's return on capital employed (ROCE) was -0.76, a 76.51% increase from the -0.43 ROCE in the previous year.

Magenta Therapeutics Aktienanalyse

What does Magenta Therapeutics do?

Magenta Therapeutics Inc is a groundbreaking biotechnology company specializing in the development of novel therapies for serious blood disorders. The company uses a unique technology platform based on stem cell transplantation and gene editing to develop innovative therapies that have the potential to improve the lives of millions of people worldwide. Magenta Therapeutics was founded in 2016 by an experienced team of executives and scientists who had previously worked in various biotech companies. The company is headquartered in Cambridge, Massachusetts, USA and has been listed on the NASDAQ stock exchange since 2018. Its business model is based on the development and commercialization of innovative therapies for blood diseases, based on a stem cell technology platform and gene editing technology. These technologies are intended to improve the treatment of blood diseases and enhance the quality of life for patients. Magenta Therapeutics has a comprehensive portfolio of therapy candidates targeting various aspects of stem cell transplantation and gene editing. These therapies aim to reduce the risks and burdens of traditional stem cell transplantation while fully harnessing the potential of stem cell transplantation to cure or alleviate blood diseases. The company has three major business areas: stem cell therapy, gene therapy, and cell therapy. In the context of these business areas, Magenta Therapeutics has already developed several therapy candidates that are currently in various stages of clinical development. The company's work is supported by a variety of financial investors, including some of the most respected names in the biotech industry. Magenta Therapeutics is also actively involved in developing partnerships with other leading companies in the biotechnology industry to further leverage the potential of its platform technology. In conclusion, Magenta Therapeutics is a young and innovative company focused on developing and commercializing new groundbreaking therapies for blood diseases. With its approach of combining stem cell technology and gene editing, the company has the potential to improve the lives of millions of patients with blood diseases while also achieving a significant return for its investors. Magenta Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Magenta Therapeutics's Return on Capital Employed (ROCE)

Magenta Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Magenta Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Magenta Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Magenta Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Magenta Therapeutics stock

What is the ROCE (Return on Capital Employed) of Magenta Therapeutics this year?

The ROCE of Magenta Therapeutics is -0.76 undefined this year.

How has the ROCE (Return on Capital Employed) of Magenta Therapeutics developed compared to the previous year?

The ROCE of Magenta Therapeutics has increased by 76.51% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Magenta Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Magenta Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Magenta Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Magenta Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Magenta Therapeutics impact the company?

An increase in the ROCE of Magenta Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Magenta Therapeutics affect the company?

A decrease in ROCE of Magenta Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Magenta Therapeutics?

Some factors that can affect Magenta Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Magenta Therapeutics so important for investors?

The ROCE of Magenta Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Magenta Therapeutics take to improve the ROCE?

To improve the ROCE, Magenta Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Magenta Therapeutics pay?

Over the past 12 months, Magenta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Magenta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Magenta Therapeutics?

The current dividend yield of Magenta Therapeutics is .

When does Magenta Therapeutics pay dividends?

Magenta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Magenta Therapeutics?

Magenta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Magenta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Magenta Therapeutics located?

Magenta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Magenta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Magenta Therapeutics from 10/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/26/2024.

When did Magenta Therapeutics pay the last dividend?

The last dividend was paid out on 10/26/2024.

What was the dividend of Magenta Therapeutics in the year 2023?

In the year 2023, Magenta Therapeutics distributed 0 USD as dividends.

In which currency does Magenta Therapeutics pay out the dividend?

The dividends of Magenta Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Magenta Therapeutics

Our stock analysis for Magenta Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Magenta Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.